GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults

European Journal of Endocrinology

Volumn 148, Issue 2, 2003, Pages 185-191

  Lanzi, Roberto ^a   Losa, Marco ^a   Villa, Isabella ^b   Gatti, Elisa ^a   Sirtori, Marcella ^b   Dal Fiume, Chiara ^b   Rubinacci, Alessandro ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM ION; DEOXYPYRIDINOLINE; GROWTH HORMONE; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; SEX HORMONE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RECEPTOR; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LUMBAR VERTEBRA; MALE; MINERAL METABOLISM; ONSET AGE; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIUS; SHORT COURSE THERAPY; TREATMENT OUTCOME; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AMINO ACIDS; CALCIUM; FEMALE; GLYCOPROTEINS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0037292935     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480185     Document Type: Article

References (47)

1. Kaufman JM, Taelman P, Vermeulen A & Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. Journal of Clinical Endocrinology and Metabolism 1992 74 118-123.
2. Amato A, Carella C, Fazio F, La Montagna G, Cittadini A, Sabatini D et al. Body composition, bone metabolism and heart structure and function in growth hormone deficient adult before and after GH replacement therapy at low doses. Journal of Clinical Endocrinology and Metabolism 1993 77 1671-1676.
3. Sartorio A, Conti A & Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgraduate Medical Journal 1993 69 846-850.
4. Bing-You RG, Denis MC & Rosen CJ. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcified Tissue International 1993 52 183-187.
5. Rosén T, Hansson T, Granhed H, Szucs J & Bengtsson B-Å. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 201-206.
6. De Boer H, Blok GJ, Van Lingen A, Teule GJ, Lips P & van der Veen EA. Consequences of childhood-onset growth hormone deficiency for adult bone mass. Journal of Bone and Mineral Research 1994 9 1319-1326.
7. Holmes SJ, Economou G, Whitehouse RW, Adams JE & Shalet SM. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1994 78 669-674.
8. Amato G, Izzo G, La Montagna G & Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clinical Endocrinology 1996 45 27-32.
9. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G & Bengtsson B-Å. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. European Journal of Endocrinology 1997 137 240-245.
10. Ohlsson C, Bengtsson B-Å, Isaksson OGP, Andreassen TT & Slootweg MC. Growth hormone and bone. Endocrine Reviews 1998 19 55-79.
11. Vandeweghe M, Taelman P & Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clinical Endocrinology 1993 39 409-415.
12. Sartorio A, Ortolani S, Galbiati E, Conte G, Vangeli V, Arosio M et al. Effects of 12-months treatment on bone metabolism and bone mineral density in adults with adult-onset GH deficiency. Journal of Endocrinological Investigation 2001 24 224-230.
13. Beshyah SA, Kyd P, Thomas E, Fairny A & Johnston DG. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults. Clinical Endocrinology 1995 42 249-254.
14. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE & Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clinical Endocrinology 1995 42 627-633.
15. Johansson G, Rosén T, Bosaeus I, Sjöström L & Bengtsson B-Å. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 1996 81 2865-2873.
16. Kann P, Piepkorn B, Schehler B, Andreas J, Lotz J, Prellwitz W et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clinical Endocrinology 1998 48 561-568.
17. Välimäki MJ, Salamela PI, Salmi J, Viikari J, Kataja M, Turunen H et al. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. European Journal of Endocrinology 1999 140 545-554.
18. Clanget C, Seck T, Hinke V, Wüster C, Ziegler R & Pfeilschifter J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clinical Endocrinology 2001 55 93-99.
19. Sneppen SB, Hoeck HC, Kolerup G, Sorensen OH, Laurberg P & Feldt-Rasmussen U. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded trial. European Journal of Endocrinology 2002 146 187-195.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001 142 5050-5055.
21. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 309-319.
22. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 39 1329-1337.
23. Lacey DL, Timms E, Tan HL, Kelly MJ, Dunstan CR, Burgess T et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 3597-3602.
24. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ & Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Journal of Bone and Mineral Research 2000 15 2-12.
25. Vidal ON, Sjogren K, Eriksson BI, Ljunggren O & Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochemical and Biophysical Research Communications 1998 248 696-700.
26. Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, Yamada N, Sugihara A, Okamura H et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochemical and Biophysical Research Communications 2001 281 361-366.
27. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K et al. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. Journal of Biological Chemistry 1998 273 27091-27096.
28. Brandstrom H, Bjorkmann T & Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochemical and Biophysical Research Communications 2001 280 831-835.
29. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC & Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999 140 4367-4370.
30. Saika M, Inoue D, Kido S & Matsumoto T. 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 2001 142 2205-2212.
31. Lee SK & Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 140 3552-3561.
32. Brandstrom H, Jonsson KB, Ohlsson C, Vidal O, Ljunghall S & Ljunggren O. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stromal cells. Biochemical and Biophysical Research Communications 1998 247 338-341.
33. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary smooth muscle cells. Biochemical and Biophysical Research Communications 2001 280 334-339.
34. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanism of glucocorticoid-induced osteoporosis. Endocrinology 1999 140 4382-4389.
35. Ueland T, Bollerslev J, Flybjerg A, Hansen TB, Vahl N & Mosekilde L. Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2002 87 2760-2763.
36. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS & Aukrust P. Increased serum osteoprotegerin by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. European Journal of Endocrinology 2001 145 685-690.
37. Ghigo E, Aimaretti G, Arvat E & Camanni F. Growth hormone releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine 2001 15 29-38.
38. Walton RJ & Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975 i 309-310.
39. Thomas MK, Lloyd-Jones DM, Thadani RI, Shaw AC, Deraska DJ, Kitch BT et al. Hypovitaminosis D in medical inpatients. New England Journal of Medicine 1998 338 777-783.
40. Schlemmer A, Johansen JS, Pedersen SA, Jørgensen JOL, Hassager C & Christiansen C. The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. Clinical Endocrinology 1991 35 471-476.
41. Johansen JS, Jensen SB, Riis BJ, Rasmussen L, Zachmann M & Christiansen C. Serum bone Gla protein: a potential member of growth hormone (GH) deficiency and the response to the GH therapy. Journal of Clinical Endocrinology and Metabolism 1990 71 122-126.
42. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB in vitro and OPG in vivo. Journal of Clinical Endocrinology and Metabolism 2002 87 4273-4279.
43. Yano K, Tsuda N, Kobayashi F, Kobayashi F, Goto M, Harada A et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 1999 14 518-527.
44. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C et al. Correlates of osteoprotegerin levels in women and men. Osteoporosis International 2002 13 394-399.
45. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M & Ho KKY. Oral estrogen antagonizes the metabolic action of growth hormone in growth hormone-deficient women. American Journal of Physiology. Endocrinology and Metabolism 2001 281 E1191-E1196.
46. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL et al. Effects of short term administration of recombinant human growth hormone to elderly people. Journal of Endocrinology and Metabolism 1990 70 519-527.
47. Tomoeda S, Nishiyama S, Nakamura T & Matsuda I. Can renal handling of phosphate predict response to growth hormone therapy in normal variant short children by short-term treatment? Acta Paediatrica 1994 83 736-740.